Turn Therapeutics Inc.
Datakwaliteit: 83%
TTRX
Nasdaq
Manufacturing
Chemicals
€ 3,50
€ 0,00
(0,00%)
Marktkapitalisatie: 104,26 M
Prijs
€ 3,50
Marktkapitalisatie
104,26 M
Dagbereik
€ 3,41 — € 3,50
52-Weeksbereik
€ 2,57 — € 26,50
Volume
14.362
Openen € 3,50
50D / 200D Gem.
€ 3,65
4,16% below
50D / 200D Gem.
€ 4,01
12,77% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -2,56 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-68,15%
Onder sectorgemiddelde (-53,41%)
ROIC-75,15%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio1,43
Interest CoverageN/A
Waardering
PE (TTM)
-32,64
Onder sectorgemiddelde (-1,48)
P/B Ratio206,85
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -32,6 | -1,5 |
| P/B | 206,9 | 1,6 |
| ROE % | -68,2 | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -3,19 M |
| ROE | -68,15% | ROA | -26,26% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -2,56 M |
| ROIC | -75,15% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 1,43 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 985.486 | Tangible Book Value | -400.866 |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -32,64 | Forward P/E | N/A |
| P/B Ratio | 206,85 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -2,46% | ||
| Market Cap | 104,26 M | Enterprise Value | 103,74 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,12 | Revenue / Share | N/A |
| FCF / Share | -0,09 | OCF / Share | -0,09 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 80,24% |
| SBC-Adj. FCF | -2,98 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 |
|---|---|
| Revenue | — |
| Net Income | -3,19 M |
| EPS (Diluted) | -0,12 |
| Gross Profit | — |
| Operating Income | -5,86 M |
| EBITDA | — |
| R&D Expenses | 265.570,0 |
| SG&A Expenses | — |
| D&A | 52.746,0 |
| Interest Expense | — |
| Income Tax | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 |
|---|---|
| Total Assets | 12,16 M |
| Total Liabilities | 7,48 M |
| Shareholders' Equity | 4,69 M |
| Total Debt | — |
| Cash & Equivalents | 4,03 M |
| Current Assets | 5,20 M |
| Current Liabilities | 6,00 M |
{"event":"ticker_viewed","properties":{"ticker":"TTRX","listing_kind":"stock","pathname":"/stocks/ttrx","exchange":"Nasdaq","country":"US"}}